openPR Logo
Press release

Clopidogrel Market - Global Industry Analysis and Forecast 2025

11-03-2017 08:41 AM CET | Health & Medicine

Press release from: TMR Research

Clopidogrel Market - Global Industry Analysis and Forecast 2025

Global Clopidogrel Market: Snapshot

Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are in clinical trials. As a result, the drug did not face much competition and has taken over the global market, with its array of application constantly expanding.

The substantial and high-level evidence gathered over the years support the use of Clopidogrel for reduction of mortality and morbidity patients with acute coronary syndrome, myocardial infarction, and a number of other indications. As a result, the drug has developed a formidable presence in the global market over the years. Moreover, the drug’s relative ease of use, low rate of incidence of adverse reactions, and good tolerability have made it the de-facto antiplatelet agent for the reduction of atherosclerotic events in patients.

Request Sample Copy of the Report@ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6

These factors have helped the global Clopidogrel market to tread along an excellent growth path in the past few years and the market is expected to embark upon a healthy growth path in the next few years as well. However, the overall profitability of the market has reduced to a certain extent owing to entry of a number of generic products post the patent expiry of Clopidogrel manufacture in 2013. Nevertheless, the vast pool of patients prescribed Clopidogrel on an annual basis across the globe will allow market players excellent growth prospects in the next few years.

Global Clopidogrel Market: Snapshot

Clopidogrel is an antiplatelet agent of thienopyridine, which is primarily used to prevent the blood clots and help against cardiovascular problems associated with the blood clotting. The medications for inhibiting blood clots after a recent heart stroke also use clopidogrel, which is a white colored powder that is insoluble in water at neutral pH but freely soluble at pH1. Clopidogrel was the second most successful drug trailing behind Pfizer’s Lipito in 2010. Sold under the brand name Plavix, and marketed by Sanofi and Bristol-Myers Squibb, the demand for clopidogrel is escalating due to the increasing number of heart attack cases across the globe.

Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6

The patent of clopidogrel manufacturing got expires on Market 31, 2012 and is expected to prompt pharmaceutical companies to venture into clopidogrel drug manufacturing. Moreover, companies such as Dr. Reddy’s have acquired the approval to manufacture clopidogrel 300mg. Furthermore, several other organizations such as Roxane Laboratories, Aurobindo Pharma, Sun Pharma, Torrent Pharmaceuticals, and Apotex Crop have gained approval for marketing clopidogrel 75mg. Clopidogrel is also used with aspirin to treat worsening chest pain and to keep blood vessels open and present blood clots after certain heart related operations.

Global Clopidogrel Market: Trends and Prospects

The primary factor for the increased demand for clopidogrel is the mounting population across the world who are suffering from cardiovascular diseases and related problems. Additionally, the changing lifestyle and increase in number of patients related with cardiovascular diseases among the emerging economies in the Asia Pacific region are also expected to be the major consumers for clopidogrel in the next six years. Moreover, the patent expiry of clopidogrel drug is anticipated to open floodgates for various pharmaceutical companies to venture into production of clopidogrel drug.

Get Discount @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6

According to the World Heart Federation, nearly 15 million people suffer from heart attack or related problems globally. Out of these, roughly six million of these patients die while another five million are disabled permanently. This vast patient base is the primary factor that will sustain the demand during the forecast period.

Global Clopidogrel Market: Geographical Outlook

Currently, North America and Europe contribute to the maximum demand for clopidogrel, owing to factors such as robust healthcare infrastructure and high affordability of the residents in this region. However, several countries in the region of Asia Pacific, such as China, India, and Japan are aggressively working towards improving their healthcare sector with the help of favorable policies by the localized governments and increasing disposable income among the urban population. Asia Pacific is home for nearly half of the world’s population, which makes for a high quantity of patient base. Additionally, these regions also have skilled labor at low cost which is encouraging players in the market to invest actively and tap the unmet demand.

Some of the key players in the global clopidogrel market are Pfizer, Dr Reddy’s, Apotex Corp, Roxane Laboratories, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharma.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.

Contact:

TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050
Email: sales@tmrresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Clopidogrel Market - Global Industry Analysis and Forecast 2025 here

News-ID: 799972 • Views:

More Releases from TMR Research

Automotive Vision System Market Share and Growth Factors Impact Analysis 2021 - 2031
Automotive Vision System Market Share and Growth Factors Impact Analysis 2021 - …
Automotive Vision System Market: Introduction A system that increases the vehicle driver's perception during night or bad weather conditions is termed as Automotive night vision system (ANVS). The system is otherwise beyond the reach of the vehicle's headlights, thereby prevents accidents at night. It can also be defined as a system which assists the driver by increasing visibility during bad whether while providing safety. Vehicle which have automotive vision system integrated are
Waste Heat Recovery Market Competitive Landscape Analysis with Forecast by 2031
Waste Heat Recovery Market Competitive Landscape Analysis with Forecast by 2031
Waste Heat Recovery Market: Snapshot The waste heat recovery market has been expected to reach a valuation of US$ 65.87 Bn and expand at a CAGR of 6.90% in the foreseeable years from 2020 to 2030. The growth opportunities in the waste heat recovery market are attributed to the increasing prices of electricity and energy in the emerging economies. In addition to this, government regulations and incentives are also estimated to contribute
Physical Fitness Equipment Market Current Trends and Future Aspect Analysis | Market has been expected to reach a valuation of US$ 14.8 Bn and expand at a CAGR of 3.3% in the foreseeable years from 2021 to 2031.
Physical Fitness Equipment Market Current Trends and Future Aspect Analysis | Ma …
Global Physical Fitness Equipment Market: Snapshot The physical fitness equipment market has been expected to reach a valuation of US$ 14.8 Bn and expand at a CAGR of 3.3% in the foreseeable years from 2020 to 2030. The revenue generation opportunities in the physical fitness equipment market are attributed to the increasing enthusiasm among people toward fitness. In recent years, the fitness industry has been growing at a noticeable speed owing to
Molecular Spectrometry Market Competitive Analysis and Forecast 2021-2031 | Growing Regions like North America, Europe and Asia Pacific.
Molecular Spectrometry Market Competitive Analysis and Forecast 2021-2031 | Grow …
Global Molecular Spectrometry Market: Snapshot  Molecular spectrometry examines and quantifies the response of molecules on interaction with known amounts of energy. Molecules have some energy levels that can be studied by determining the molecule's energy exchange through emission or absorbance. Molecular spectrometry involves studying emission, absorption, or scattering of electromagnetic waves by atoms or molecules to quantitatively and qualitatively study atoms, molecules or physical processes. The interaction of matter with radiation

All 5 Releases


More Releases for Clopidogrel

Clopidogrel Bisulfate Market 2021: Global Industry Analysis Report to 2027
The global clopidogrel bisulfate market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Clopidogrel bisulfate is used for the treatment of serious or life-threatening problems with the heart and blood vessels. It is given to people who have had a stroke, heart attack, or severe chest pain. The major factor for the growth of the market during the forecast period is the increasing demand for
Global Clopidogrel Market Insights, Forecast
Clopidogrel, sold as the brandname Plavix among others, is an antiplatelet medication that is used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent. It is taken by mouth. Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians
Clopidogrel Market blustery by 2025
Global Clopidogrel Market: Snapshot Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are
Clopidogrel Market - Future demand Foreseen by 2025
Global Clopidogrel Market: Snapshot Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are
Clopidogrel Market - Geographical Outlook and Forecast 2017 - 2025
Global Clopidogrel Market: Snapshot Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are
Clopidogrel Market : Global Industry Analysis and Opportunity Assessment 2017 - …
Global Clopidogrel Market: Snapshot Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are